1. Scrip
  2. >>Business

COVID-19 Vaccine Results A Breakthrough Moment For BioNTech

Founder Considers Its Focus To Be Immunotherapy, Not mRNA

 
• By Andrew McConaghie

Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
BNT162b1 may become known as the 'Pfizer vaccine' but BioNTech will be transformed by its likely success.

The topline results from Pfizer and BioNTech’s COVID-19 vaccine Phase III trial look to be a breakthrough for the German biotech as well as the world. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.